BiotechTube

Pegcetacoplan + Placebo matching Pegcetacoplan

Phase 3Completed
0 watching 0 views this week📈 Rising
76
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cold Agglutinin Disease

Conditions

Cold Agglutinin Disease

Trial Timeline

Oct 20, 2022 → Sep 11, 2024

NCT ID
NCT05096403

About Pegcetacoplan + Placebo matching Pegcetacoplan

Pegcetacoplan + Placebo matching Pegcetacoplan is a phase 3 stage product being developed by Swedish Orphan Biovitrum for Cold Agglutinin Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05096403. Target conditions include Cold Agglutinin Disease.

Hype Score Breakdown

Clinical
27
Activity
18
Company
9
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT05096403Phase 3Completed

Competing Products

20 competing products in Cold Agglutinin Disease

See all competitors
ProductCompanyStageHype Score
THB001Third Harmonic BioPhase 1
25
Nasal Glucagon + OxymetazolineEli LillyPhase 1
33
New Formulation Phenylephrine HCl + Marketed Phenylephrine HCl + PlaceboJohnson & JohnsonPhase 2
52
Pseudoephedrine/ParacetamolJohnson & JohnsonApproved
85
DFV890NovartisPhase 2
52
Lidocaine 8mg + CPC 2mg + Lidocaine 1mg + CPC 2mgNovartisPhase 3
77
Omalizumab + Omalizumab + PlaceboNovartisPhase 2
52
Dextromethorphan + PlaceboNovartisApproved
85
XylometazolineNovartisPhase 3
77
Penciclovir + PlaceboNovartisApproved
85
N-acetylcysteine + PlaceboNovartisPhase 2
52
Advil Congestion Relief + Advil Allergy and Congestion Relief + ParacetamolPfizerPhase 3
76
pseudoephedrine hydrochloride 30 mg tablets + Placebo tabletsPfizerPhase 3
76
sutimlimabSanofiPhase 3
76
sutimlimab (BIVV009) + placeboSanofiPhase 3
76
Dupilumab SAR231893 + Placebo + Non sedating H1-antihistamineSanofiPhase 3
76
BIVV009SanofiPhase 3
76
rilonacept 160 mg + Placebo + rilonacept 160 mgRegeneron PharmaceuticalsPhase 3
76
Rilonacept + PlaceboRegeneron PharmaceuticalsPhase 2
51
HSK39004 Dry Powder Inhaler -0.75mg BID + HSK39004 Dry Powder Inhaler -1.5mg BID + HSK39004 Inhalation Suspension -3mg BID + HSK39004 PlaceboHaisco Pharmaceutical GroupPhase 2
49

Other Products from Swedish Orphan Biovitrum

Recombinant coagulation factor (rFVIIIFc)Approved
84
rFVIIIFcApproved
84
AnakinraApproved
84
Efanesoctocog alfaApproved
84
Kepivance (Palifermin)Approved
84